No Cardiac Safety Concerns Reported with a Pharmaceutically Manufactured Cannabidiol Formulation

No cardiac safety concerns reported with a pharmaceutically manufactured cannabidiol formulation

A pharmaceutically produced cannabidiol formulation had a good overall safety profile, including cardiac safety, according to research presented at Heart Failure 2025.

Pharmaceutical-Grade Cannabidiol Shows No Cardiac Safety Concerns, Study

A recent clinical investigation presented at Heart Failure 2025, the premier scientific congress held by the European Society of Cardiology, has brought to light promising findings regarding the safety of a pharmaceutically manufactured cannabidiol formulation in patients with increased cardiovascular risk. This study, conducted within a rigorous placebo-controlled framework, evaluated both the general safety and, critically, the cardiac safety …